Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
about
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implicationsRenal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouseMechanism-based inactivation of CYP450 enzymes: a case study of lapatinibPorphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.Partial protoporphyrinogen oxidase (PPOX) gene deletions, due to different Alu-mediated mechanisms, identified by MLPA analysis in patients with variegate porphyriaEvaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.Plasma and red cell exchange transfusions for erythropoietic protoporphyria: a case report and review of the literature.Drugs and acute porphyrias: reasons for a hazardous relationship.Update review of the acute porphyrias.Acute intermittent porphyria precipitated by atazanavir/ritonavir.Acute hepatic porphyrias: Recommendations for evaluation and long-term management.Identification of an AluY-mediated deletion of exon 5 in the CPOX gene by MLPA analysis in patients with hereditary coproporphyria.ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice.The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.Many pitfalls in diagnosis of acute intermittent porphyria: a case report
P2860
Q27005605-146E093B-E61B-4872-AFD8-1412569F9FB7Q27307650-64F37CD5-F8FC-4705-B833-192208C6524DQ28080497-64709729-F789-402F-B3E3-B2F063534ADBQ36267789-CB4F32DA-A56D-4F48-B11A-41599C942035Q36561191-B7B95714-019C-42B9-946B-D77C33E3302FQ37355935-543214F2-37C9-4EEE-9B86-027123E7196EQ38045267-8297C273-7656-45B8-9B4C-7E8A7B35D907Q38267141-38B0C9A9-51BC-4CB4-95A3-13660F4AA03BQ39041104-62EBC814-9764-4091-882C-78BC325997CDQ40000652-10C558F7-76B7-4077-856C-631268B883C1Q46425849-2A053FCC-89B8-4562-9DFA-75F1EA8A3997Q51381887-CBACC43D-A79C-4FC7-AD40-1CDDE1A3C176Q54551135-D0B56A3E-CB51-4E83-B2D8-15BB3E8D7790Q55426998-61C0E427-5A6E-4E08-B279-2F7098C06FDDQ58803929-778E31F9-0066-466E-AD87-9423F2BE178E
P2860
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@ast
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@en
type
label
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@ast
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@en
prefLabel
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@ast
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@en
P2093
P2860
P1476
Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias.
@en
P2093
Stig Thunell
P2860
P304
P356
10.1111/J.0306-5251.2007.02955.X
P407
P577
2007-06-19T00:00:00Z